What is Zacks Research’s Estimate for CRDF FY2026 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Analysts at Zacks Research increased their FY2026 EPS estimates for Cardiff Oncology in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.74) for the year, up from their prior estimate of ($0.81). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.67) per share. Zacks Research also issued estimates for Cardiff Oncology’s FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.74) EPS.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million.

A number of other brokerages have also recently issued reports on CRDF. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Monday, May 18th. Wall Street Zen cut shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Piper Sandler reduced their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cardiff Oncology has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $1.81 on Thursday. Cardiff Oncology has a 52-week low of $1.48 and a 52-week high of $4.56. The stock has a market cap of $123.75 million, a PE ratio of -2.70 and a beta of 1.36. The firm’s 50 day moving average price is $1.69 and its two-hundred day moving average price is $2.05.

Hedge Funds Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Advisors Wealth Management LLC bought a new position in shares of Cardiff Oncology during the fourth quarter worth $30,000. Tamar Securities LLC bought a new position in shares of Cardiff Oncology during the fourth quarter worth $32,000. Brooklyn Investment Group bought a new position in shares of Cardiff Oncology during the third quarter worth $26,000. R Squared Ltd bought a new position in shares of Cardiff Oncology during the fourth quarter worth $36,000. Finally, Engineers Gate Manager LP bought a new position in shares of Cardiff Oncology during the second quarter worth $43,000. 16.29% of the stock is owned by institutional investors.

Trending Headlines about Cardiff Oncology

Here are the key news stories impacting Cardiff Oncology this week:

• Neutral Sentiment: Zacks Research reiterated that Cardiff Oncology is expected to remain unprofitable, with FY2026 EPS at $(0.74), FY2027 at $(0.76), and FY2028 at $(0.74), while the current full-year consensus is $(0.67).
• Neutral Sentiment: Zacks also projected quarterly losses for Q2 2026, Q3 2026, and Q4 2026 in the range of $(0.18) to $(0.20) per share, suggesting no near-term profitability inflection.
• Neutral Sentiment: Noble Financial similarly forecast ongoing quarterly losses and said FY2026 EPS should be $(0.78), reinforcing the view that Cardiff Oncology remains a pre-profit biotech with limited earnings visibility.
• Negative Sentiment: Noble Financial cut its Q2 2026 and Q3 2026 EPS estimates, indicating analysts are becoming more conservative about Cardiff Oncology’s near-term financial outlook.
• Negative Sentiment: Zacks lowered its FY2027 EPS estimate to $(0.76) from $(0.75), a small but negative revision that may weigh on sentiment.
• Negative Sentiment: Recent earnings estimates remain below zero across the board, which can pressure CRDF shares as investors wait for clearer clinical or commercial catalysts.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.